<DOC>
	<DOCNO>NCT01720043</DOCNO>
	<brief_summary>To evaluate effect VELCADE platelet aggregation baseline , 24 hour 48 hour infusion patient multiple myeloma</brief_summary>
	<brief_title>Hemostatic Effects VELCADEÂ®* Treatment Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients diagnosis multiple myeloma Patients receive VELCADE least 2 week receive treatment VELCADE platelet aggregation test Patients instructed take aspirin ibuprofen 710 day prior platelet aggregation test . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal least 1 year screen visit , surgically sterilize childbearing potential , agree practice 2 effective method contraception time sign informed consent form 30 day last dose VELCADE , agree completely abstain heterosexual intercourse . Male subject , even surgically sterilize ( ie , status postvasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Patients receive Velcade within 2 week prior study registration Patient platelet count &lt; 150,000 within 7 day enrollment . Patient absolute neutrophil count &lt; 1000 within 7 day enrollment . Patient &gt; 1.5 x ULN Total Bilirubin Patient &gt; Grade 2 peripheral neuropathy Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . Currently receive medication Coumadin , heparin , low molecular weight heparin , NSAIDS . Concomitant use medication must discontinue within two week prior begin protocol treatment . Patient hypersensitivity VELCADE , boron , mannitol . Female subject pregnant lactating . Confirmation subject pregnant must establish negative serum pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Female patient lactate positive serum pregnancy test screening period , positive urine pregnancy test Day 1 first dose study drug , applicable . Serious medical psychiatric illness likely interfere participation clinical study . Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial . Radiation therapy within 3 week randomization . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>multiple myeloma</keyword>
</DOC>